MX2020007081A - Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad. - Google Patents

Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad.

Info

Publication number
MX2020007081A
MX2020007081A MX2020007081A MX2020007081A MX2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A MX 2020007081 A MX2020007081 A MX 2020007081A
Authority
MX
Mexico
Prior art keywords
methods
peptides
cells
materials
diabetes
Prior art date
Application number
MX2020007081A
Other languages
English (en)
Inventor
Jr David Hal Wagner
Martin Glenn Yussman
Charles W Henry
Original Assignee
Op T Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/184,129 external-priority patent/US20190194290A1/en
Application filed by Op T Llc filed Critical Op T Llc
Publication of MX2020007081A publication Critical patent/MX2020007081A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)

Abstract

Se describen métodos y materiales para prevenir y modular aterosclerosis. En particular, los péptidos pequeños son capaces de interactuar con CD40, interfiriendo de esta manera con la capacidad de CD40 a interactuar con CD154, que impacta la inflamación y la aterosclerosis. El uso de estos péptidos en reducir aterosclerosis, y en particular, la respuesta inflamatoria autoinmunitaria que puede ser un factor de conducción del mismo. El uso de estos péptidos cortos para reducir el colesterol LDL. Métodos y materiales para detectar células T que expresan CD40 (células Th40). Métodos y materiales para prevenir, modular, reducir y/o revertir la diabetes tipo 2 y enfermedad auto-inflamatoria. En particular, los péptidos pequeños son capaces de interactuar con CD40, interfiriendo de esta manera con la capacidad de CD40 de interactuar con CD154, lo cual impacta la inflamación y la diabetes tipo 2. El uso de estos péptidos en reducir diabetes Tipo 2, y en particular, la respuesta inflamatoria autoinmunitaria que puede ser un factor de conducción del mismo. El uso de estos péptidos cortos para reducir IL2, INF?, e IL17a. El uso de estos péptidos para incrementar la proteína de transporte de glucosa (GLUT4). Métodos y materiales para detectar células T que expresan CD40 (células Th40).
MX2020007081A 2018-01-05 2019-01-04 Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad. MX2020007081A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614262P 2018-01-05 2018-01-05
US16/184,129 US20190194290A1 (en) 2010-10-19 2018-11-08 Methods for preventing, modulating and/or reducing cardiovascular disease
PCT/US2019/012425 WO2019136307A1 (en) 2018-01-05 2019-01-04 Therapeutic peptides and methods for treating autoimmune related disease

Publications (1)

Publication Number Publication Date
MX2020007081A true MX2020007081A (es) 2020-10-28

Family

ID=67144298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007081A MX2020007081A (es) 2018-01-05 2019-01-04 Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad.

Country Status (9)

Country Link
EP (1) EP3735260A4 (es)
JP (1) JP7511242B2 (es)
CN (1) CN111801110A (es)
AU (1) AU2019205328A1 (es)
BR (1) BR112020013716A2 (es)
CA (1) CA3086193A1 (es)
MX (1) MX2020007081A (es)
SG (1) SG11202006494VA (es)
WO (1) WO2019136307A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3421487B1 (en) 2010-10-19 2023-06-28 The Regents of the University of Colorado, a body corporate Peptides for modulating t-cell activity and uses thereof
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
EP3996731A4 (en) 2019-07-12 2023-07-12 Op-T Llc PEPTIDES AND METHODS OF TREATING DISEASES
EP4135742A2 (en) * 2020-04-17 2023-02-22 Op-T Llc Bioactive peptides and methods of use thereof
WO2021231898A2 (en) * 2020-05-14 2021-11-18 Op-T Llc Nanoparticle compositions and uses thereof
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
EP1649282A4 (en) * 2003-07-07 2007-08-29 Webb Waring Inst PROCESS FOR PREDICTING THE DEVELOPMENT OF AUTOIMMUNE DISEASES AND TREATMENT THEREOF
US7449200B2 (en) * 2006-04-17 2008-11-11 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means
EP3421487B1 (en) * 2010-10-19 2023-06-28 The Regents of the University of Colorado, a body corporate Peptides for modulating t-cell activity and uses thereof
WO2013192504A1 (en) * 2012-06-22 2013-12-27 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
US20170108514A1 (en) * 2014-03-23 2017-04-20 The Regents Of The University Of Colorado, A Body Corporate Diagnosis of multiple sclerosis in human and animal subjects

Also Published As

Publication number Publication date
BR112020013716A2 (pt) 2020-12-22
JP7511242B2 (ja) 2024-07-05
SG11202006494VA (en) 2020-08-28
EP3735260A4 (en) 2021-12-08
JP2021510174A (ja) 2021-04-15
CA3086193A1 (en) 2019-07-11
AU2019205328A1 (en) 2020-08-06
WO2019136307A1 (en) 2019-07-11
EP3735260A1 (en) 2020-11-11
CN111801110A (zh) 2020-10-20

Similar Documents

Publication Publication Date Title
MX2020007081A (es) Peptidos terapeuticos y metodos para tratar enfermedad relacionada con la autoinmunidad.
Umar et al. Role of vitamin D beyond the skeletal function: a review of the molecular and clinical studies
EA201291233A1 (ru) Аналоги глюкагона
TN2012000560A1 (en) Glucagon analogues
EA201590294A1 (ru) Аналоги глюкагона
MX2011006320A (es) Analogos de glucagon.
Mousa et al. Advances in pharmacotherapy for primary biliary cirrhosis
PH12016500675B1 (en) Acylated glucagon analogues
GEP20146056B (en) Acylated glucagon analogues
SA518400233B1 (ar) علاج جيني لعلاج نزف الدم الوراثي a
EP2799447A3 (en) Glucagon analogues
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
ATE520714T1 (de) Glucagonanaloga
MX2017012864A (es) Analogo acilado del glucagon.
CY1121332T1 (el) Μiμhtiκα καλσιτονινης προς θεραπεια ασθενειων και διαταραχων
BR112014008249A2 (pt) affenadenovirus (gorilla) ou vetores adenovirais e métodos de uso
EP3421487A3 (en) Peptides for modulating t-cell activity and uses thereof
RU2013157300A (ru) Система полицистронной экспрессии для бактерий
AR080027A1 (es) Proteinas de union a cd127
PE20191529A1 (es) Peptidos y metodos para el tratamiento de diabetes
WO2016105545A3 (en) Insulin analogues with enhanced stabilized and reduced mitogenicity
WO2018197895A3 (en) PARATHYROID HORMONE FUSION POLYPEPTIDE
WO2006083516A3 (en) Modified cyanovirin-n polypeptide
Chen et al. Efficient production of recombinant IL-21 proteins for pre-clinical studies by a two-step dilution refolding method
Jenkins et al. Targeting mechanisms for natural killer cell dysfunction in patients with multiple myeloma